CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: RAB11FIP3 (ImmuneEditome ID:9727)

1. Gene summary of enriched editing regions for RAB11FIP3

check button Gene summary
Gene informationGene symbol

RAB11FIP3

Gene ID

9727

GeneSynonymsCART1|FIP3-Rab11|Rab11-FIP3
GeneCytomap

16p13.3

GeneTypeprotein-coding
GeneDescriptionrab11 family-interacting protein 3|EF hands-containing Rab-interacting protein|MU-MB-17.148|RAB11 family interacting protein 3 (class II)|arfophilin-1|cytoplasmic adaptor for RAR and TR|eferin
GeneModificationdate20230329
UniprotIDO75154;H0Y7F9;X6RFI8;A0A0J9YWV4;F6X994;A0A0J9YXZ3;A0A0A0MSV1;A0A0J9YY48;A0A0J9YWM0
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr16:476634-477056:+ENST00000483002.1ENSG00000090565.14RAB11FIP3ncRNA_intronicAluSg,AluSz6chr16:476634-477056:+.alignment
chr16:492931-494199:+ENST00000495663.1ENSG00000090565.14RAB11FIP3ncRNA_intronicAluYc,AluSz6chr16:492931-494199:+.alignment
chr16:495831-496042:+ENST00000495663.1ENSG00000090565.14RAB11FIP3ncRNA_intronicAluSpchr16:495831-496042:+.alignment
chr16:497995-500616:+ENST00000262305.7ENSG00000090565.14RAB11FIP3intronicAluSp,(TTTCTC)n,AluSx3,AluJb,FAM,AluSgchr16:497995-500616:+.alignment
chr16:497995-500616:+ENST00000434585.4ENSG00000090565.14RAB11FIP3intronicAluSp,(TTTCTC)n,AluSx3,AluJb,FAM,AluSgchr16:497995-500616:+.alignment
chr16:497995-500616:+ENST00000449879.4ENSG00000090565.14RAB11FIP3intronicAluSp,(TTTCTC)n,AluSx3,AluJb,FAM,AluSgchr16:497995-500616:+.alignment
chr16:497995-500616:+ENST00000450428.4ENSG00000090565.14RAB11FIP3intronicAluSp,(TTTCTC)n,AluSx3,AluJb,FAM,AluSgchr16:497995-500616:+.alignment
chr16:497995-500616:+ENST00000452814.4ENSG00000090565.14RAB11FIP3intronicAluSp,(TTTCTC)n,AluSx3,AluJb,FAM,AluSgchr16:497995-500616:+.alignment
chr16:517369-518240:+ENST00000461009.1ENSG00000090565.14RAB11FIP3ncRNA_intronicL1MC3,AluJo,AluJr,AluYchr16:517369-518240:+.alignment
chr16:517369-518240:+ENST00000464263.1ENSG00000090565.14RAB11FIP3ncRNA_intronicL1MC3,AluJo,AluJr,AluYchr16:517369-518240:+.alignment
chr16:517369-518240:+ENST00000487899.1ENSG00000090565.14RAB11FIP3ncRNA_intronicL1MC3,AluJo,AluJr,AluYchr16:517369-518240:+.alignment


Top

2. Tumor-specific enriched editing regions for RAB11FIP3


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr16:497995-500616:+KIRCEER3.5247e-02image
ENSG00000090565.14,RAB11FIP3KIRCEAG4.8666e-02image
chr16:497995-500616:+KIRPEER1.1774e-02image
ENSG00000090565.14,RAB11FIP3KIRPEAG7.4137e-03image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for RAB11FIP3


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr16:497995-500616:+LAMLEERENSG00000090565,RAB11FIP3-0.42677.1857e-033.8684e-08-0.4500imageNADAR;CSTF2T;DHX9;DKC1;EIF4A3;ELAVL1;FBL;FUS;HNRNPC;HNRNPK;IGF2BP2;NOP56;NOP58;TARDBP;U2AF2;UPF1RAB11FIP3MonocytesGSVA_HALLMARK_PANCREAS_BETA_CELLS
chr16:497995-500616:+LAMLEERENSG00000090565,RAB11FIP3-0.42677.1857e-033.8684e-08-0.4500imageNADAR;CSTF2T;DHX9;DKC1;EIF4A3;ELAVL1;FBL;FUS;HNRNPC;HNRNPK;IGF2BP2;NOP56;NOP58;TARDBP;U2AF2;UPF1RAB11FIP3MonocytesGSVA_HALLMARK_PANCREAS_BETA_CELLS
chr16:497995-500616:+LAMLEERENSG00000090565,RAB11FIP3-0.42677.1857e-033.8684e-08-0.4500imageNADAR;CSTF2T;DHX9;DKC1;EIF4A3;ELAVL1;FBL;FUS;HNRNPC;HNRNPK;IGF2BP2;NOP56;NOP58;TARDBP;U2AF2;UPF1RAB11FIP3MonocytesGSVA_HALLMARK_PANCREAS_BETA_CELLS
chr16:497995-500616:+LAMLEERENSG00000090565,RAB11FIP3-0.42677.1857e-033.8684e-08-0.4500imageNADAR;CSTF2T;DHX9;DKC1;EIF4A3;ELAVL1;FBL;FUS;HNRNPC;HNRNPK;IGF2BP2;NOP56;NOP58;TARDBP;U2AF2;UPF1RAB11FIP3MonocytesGSVA_HALLMARK_PANCREAS_BETA_CELLS
chr16:497995-500616:+LAMLEERENSG00000090565,RAB11FIP3-0.42677.1857e-033.8684e-08-0.4500imageNADAR;CSTF2T;DHX9;DKC1;EIF4A3;ELAVL1;FBL;FUS;HNRNPC;HNRNPK;IGF2BP2;NOP56;NOP58;TARDBP;U2AF2;UPF1RAB11FIP3MonocytesGSVA_HALLMARK_PANCREAS_BETA_CELLS

More results



Top

4. Enriched editing regions and immune related splicing for RAB11FIP3


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000090565.14,RAB11FIP3
ESCAEAGA5ENSG00000165494.6chr1183168427:83168687:83167414:83167505:83167414:83167898-0.43966.3444e-031.1329e-05-0.4000imageNACIN1;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NCBP3;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;WTAP;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NAT_cells_CD4_memory_resting
chr16:497995-500616:+
KIRCEERIRENSG00000010295.15chr126548064:6548157:6548424:6548545-0.32544.3988e-061.3128e-12-0.4148imageNADAR;CSTF2T;DHX9;DKC1;EIF4A3;ELAVL1;FBL;FUS;HNRNPC;HNRNPK;IGF2BP2;NOP56;NOP58;TARDBP;U2AF2;UPF1NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr16:497995-500616:+
KIRCEERIRENSG00000110274.10chr11117394919:117395191:117395546:117395722-0.34029.0586e-082.6170e-11-0.4155imageNADAR;CSTF2T;DHX9;DKC1;EIF4A3;ELAVL1;FBL;FUS;HNRNPC;HNRNPK;IGF2BP2;NOP56;NOP58;TARDBP;U2AF2;UPF1NAMast_cells_restingGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr16:497995-500616:+
KIRCEERIRENSG00000143554.9chr1153777760:153778885:153779113:153779211-0.37771.0642e-071.5032e-12-0.4062imageNCSTF2T;DKC1;EIF4A3;ELAVL1;FBL;FUS;HNRNPC;HNRNPK;IGF2BP2;NOP58;U2AF2;UPF1NAB_cells_naiveGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
ENSG00000090565.14,RAB11FIP3
KIRCEAGIRENSG00000133619.13chr7149714780:149715066:149719545:149719672-0.30464.7609e-071.1079e-09-0.4012imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX42;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;WTAP;XRN2;YTHDF1;YWHAG;ZNF184NAB_cells_naiveGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
ENSG00000090565.14,RAB11FIP3
KIRCEAGIRENSG00000149657.15chr2062126225:62126439:62127584:62127701-0.30202.6080e-063.9266e-10-0.4076imageNADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM5;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184LSM14BB_cells_naiveGSVA_HALLMARK_UV_RESPONSE_UP
ENSG00000090565.14,RAB11FIP3
KIRCEAGIRENSG00000166888.6chr1257102828:57102921:57104326:57104586-0.27862.6995e-064.1697e-11-0.4031imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CPSF6;CSTF2T;DDX42;DGCR8;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP7;LIN28;LIN28B;LSM11;MBNL2;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM22;RBM5;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184STAT6T_cells_CD4_memory_activatedGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
ENSG00000090565.14,RAB11FIP3
KIRCEAGIRENSG00000010295.15chr126548064:6548157:6548424:6548545-0.33062.7918e-061.5229e-12-0.4137imageNADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CSTF2T;DDX54;DGCR8;DHX9;DKC1;EIF4A3;ELAVL1;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;LIN28;LIN28A;LIN28B;MOV10;MSI1;MSI2;NCBP3;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;U2AF1;U2AF2;UPF1;VIM;ZNF184NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
ENSG00000090565.14,RAB11FIP3
KIRCEAGIRENSG00000139636.11chr1249100387:49100646:49101249:49101263-0.35596.1410e-072.8945e-12-0.4014imageNACIN1;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX42;DDX54;DGCR8;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184LMBR1LMacrophages_M1GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr16:497995-500616:+
KIRCEERIRENSG00000140398.9chr1575351945:75352701:75353738:75353866-0.29771.1217e-064.9396e-11-0.4218imageNADAR;CSTF2T;DHX9;EIF4A3;ELAVL1;FBL;FUS;HNRNPC;HNRNPK;NOP56;NOP58;TARDBP;U2AF2NAT_cells_follicular_helperGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE

More results



Top

5. Enriched editing regions and immune infiltration for RAB11FIP3


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr16:497995-500616:+BLCAEERNK_cells_resting1.5525e-02-0.2946image
chr16:497995-500616:+BRCAEERB_cells_naive2.4457e-030.1352image
ENSG00000090565.14,RAB11FIP3BRCAEAGB_cells_naive6.4053e-030.1209image
chr16:497995-500616:+COADEERDendritic_cells_activated1.4679e-020.3929image
ENSG00000090565.14,RAB11FIP3COADEAGDendritic_cells_activated8.9046e-030.4134image
chr16:497995-500616:+ESCAEERDendritic_cells_activated6.9175e-03-0.2538image
ENSG00000090565.14,RAB11FIP3ESCAEAGDendritic_cells_activated3.3981e-02-0.1979image
chr16:497995-500616:+GBMEERMacrophages_M18.1179e-03-0.2620image
ENSG00000090565.14,RAB11FIP3GBMEAGMacrophages_M16.7585e-03-0.2679image
chr16:495831-496042:+KIRCEERMonocytes2.3653e-020.2048image
chr16:497995-500616:+KIRCEERDendritic_cells_activated7.7725e-030.1585image
ENSG00000090565.14,RAB11FIP3KIRCEAGDendritic_cells_activated4.5785e-030.1684image
chr16:492931-494199:+LAMLEERPlasma_cells3.6945e-02-0.3646image
chr16:497995-500616:+LAMLEERMacrophages_M11.8844e-020.2012image
ENSG00000090565.14,RAB11FIP3LAMLEAGMacrophages_M11.5461e-020.2073image
chr16:497995-500616:+LGGEERNK_cells_resting3.5293e-020.1212image
ENSG00000090565.14,RAB11FIP3LGGEAGNK_cells_resting2.6128e-020.1276image
chr16:497995-500616:+LUADEERMacrophages_M24.6078e-020.1631image
chr16:497995-500616:+OVEERT_cells_gamma_delta7.2654e-040.2582image
ENSG00000090565.14,RAB11FIP3OVEAGT_cells_gamma_delta2.8239e-040.2712image
chr16:497995-500616:+PCPGEERDendritic_cells_resting1.7451e-02-0.5014image
ENSG00000090565.14,RAB11FIP3PCPGEAGDendritic_cells_resting1.6856e-02-0.5037image
chr16:497995-500616:+PRADEERB_cells_memory4.7837e-02-0.2445image
ENSG00000090565.14,RAB11FIP3PRADEAGDendritic_cells_activated2.6240e-030.3518image
chr16:497995-500616:+SARCEERMacrophages_M04.2605e-02-0.3447image
ENSG00000090565.14,RAB11FIP3SARCEAGMacrophages_M03.4425e-02-0.3440image
chr16:497995-500616:+SKCMEERNeutrophils7.6245e-030.3058image
ENSG00000090565.14,RAB11FIP3SKCMEAGNeutrophils7.2665e-030.3076image
chr16:492931-494199:+STADEERMonocytes8.2191e-03-0.3628image
chr16:497995-500616:+STADEERDendritic_cells_activated2.1282e-020.1620image
ENSG00000090565.14,RAB11FIP3STADEAGDendritic_cells_activated7.0594e-030.1850image
chr16:497995-500616:+TGCTEERT_cells_CD4_memory_resting1.3477e-020.3829image
ENSG00000090565.14,RAB11FIP3TGCTEAGT_cells_CD4_memory_resting1.1291e-020.3918image
chr16:497995-500616:+UCECEERT_cells_CD4_memory_activated2.0114e-020.4368image


Top

6. Enriched editing regions and immune gene sets for RAB11FIP3


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
chr16:497995-500616:+PRADEER5.5211e-030.33792.0215e-020.28531.6175e-030.38069.5814e-040.3972image
ENSG00000090565.14,RAB11FIP3STADEAG1.2237e-030.22114.0958e-020.14081.8207e-030.21344.3734e-030.1955image
chr16:497995-500616:+STADEER5.3675e-040.24144.7763e-020.13955.4072e-040.24135.2999e-050.2804image
chr16:497995-500616:+UCECEER2.1043e-020.43403.6363e-020.39722.4082e-020.42521.6785e-020.4481image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000090565.14,RAB11FIP3BLCAGSVA_HALLMARK_DNA_REPAIREAG1.5804e-02-0.2917image
chr16:497995-500616:+BLCAGSVA_HALLMARK_DNA_REPAIREER1.1024e-02-0.3087image
chr16:497995-500616:+BRCAGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER1.2271e-040.1709image
ENSG00000090565.14,RAB11FIP3BRCAGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG5.6560e-060.2000image
ENSG00000090565.14,RAB11FIP3CESCGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEAG2.8490e-020.3652image
chr16:497995-500616:+CESCGSVA_HALLMARK_HYPOXIAEER2.8111e-020.3661image
chr16:497995-500616:+ESCAGSVA_HALLMARK_MYOGENESISEER2.7819e-030.2801image
ENSG00000090565.14,RAB11FIP3ESCAGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG8.5174e-040.3068image
ENSG00000090565.14,RAB11FIP3GBMGSVA_HALLMARK_HEME_METABOLISMEAG2.6212e-080.5194image
chr16:497995-500616:+GBMGSVA_HALLMARK_HEME_METABOLISMEER3.7483e-080.5144image
ENSG00000090565.14,RAB11FIP3KIRCGSVA_HALLMARK_MYC_TARGETS_V1EAG2.7311e-080.3235image
chr16:495831-496042:+KIRCGSVA_HALLMARK_DNA_REPAIREER2.5800e-040.3252image
chr16:492931-494199:+KIRCGSVA_HALLMARK_COAGULATIONEER1.1876e-040.3828image
chr16:497995-500616:+KIRCGSVA_HALLMARK_MYC_TARGETS_V1EER2.3468e-080.3255image
chr16:497995-500616:+KIRPGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEER6.7942e-040.2683image
ENSG00000090565.14,RAB11FIP3KIRPGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG6.1541e-040.2704image
chr16:492931-494199:+LAMLGSVA_HALLMARK_SPERMATOGENESISEER2.0065e-02-0.4030image
chr16:497995-500616:+LAMLGSVA_HALLMARK_TGF_BETA_SIGNALINGEER1.1188e-020.2169image
ENSG00000090565.14,RAB11FIP3LAMLGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG1.2130e-020.2146image
chr16:497995-500616:+LGGGSVA_HALLMARK_HEME_METABOLISMEER6.3033e-040.1956image
ENSG00000090565.14,RAB11FIP3LGGGSVA_HALLMARK_HEME_METABOLISMEAG5.4391e-040.1972image
ENSG00000090565.14,RAB11FIP3LUADGSVA_HALLMARK_UV_RESPONSE_UPEAG4.6177e-030.2301image
chr16:497995-500616:+LUADGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEER7.4153e-030.2178image
ENSG00000090565.14,RAB11FIP3LUSCGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG4.3537e-020.2182image
chr16:497995-500616:+LUSCGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER4.5987e-020.2158image
ENSG00000090565.14,RAB11FIP3OVGSVA_HALLMARK_DNA_REPAIREAG2.0202e-040.2774image
chr16:497995-500616:+OVGSVA_HALLMARK_DNA_REPAIREER3.6044e-050.3130image
ENSG00000090565.14,RAB11FIP3PCPGGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG2.5298e-02-0.4755image
chr16:497995-500616:+PCPGGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER2.4765e-02-0.4771image
ENSG00000090565.14,RAB11FIP3PRADGSVA_HALLMARK_NOTCH_SIGNALINGEAG9.8988e-040.3827image
chr16:497995-500616:+PRADGSVA_HALLMARK_HEME_METABOLISMEER5.7823e-060.5258image
ENSG00000090565.14,RAB11FIP3SARCGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.3763e-030.5004image
chr16:497995-500616:+SARCGSVA_HALLMARK_UV_RESPONSE_DNEER9.7995e-050.6106image
ENSG00000090565.14,RAB11FIP3SKCMGSVA_HALLMARK_MITOTIC_SPINDLEEAG4.8886e-020.2282image
chr16:497995-500616:+SKCMGSVA_HALLMARK_MITOTIC_SPINDLEEER4.1709e-020.2358image
chr16:492931-494199:+STADGSVA_HALLMARK_BILE_ACID_METABOLISMEER6.1714e-040.4592image
chr16:497995-500616:+STADGSVA_HALLMARK_P53_PATHWAYEER1.0780e-060.3352image
ENSG00000090565.14,RAB11FIP3STADGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG4.2000e-050.2781image
chr16:497995-500616:+TGCTGSVA_HALLMARK_MITOTIC_SPINDLEEER1.8854e-020.3653image
ENSG00000090565.14,RAB11FIP3TGCTGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.6370e-020.3728image
chr16:497995-500616:+THCAGSVA_HALLMARK_MYC_TARGETS_V2EER1.2728e-020.4004image
ENSG00000090565.14,RAB11FIP3THCAGSVA_HALLMARK_MYC_TARGETS_V2EAG1.2753e-020.4003image
chr16:497995-500616:+UCECGSVA_HALLMARK_MITOTIC_SPINDLEEER5.3519e-030.5120image
ENSG00000090565.14,RAB11FIP3UCECGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEAG5.1927e-030.4971image


Top

7. Enriched editing regions and drugs for RAB11FIP3


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr16:497995-500616:+BLCAEmbelinEER7.3056e-03-0.3249image
ENSG00000090565.14,RAB11FIP3BLCAJNK.9LEAG9.5558e-03-0.3122image
chr16:497995-500616:+BRCADMOGEER2.8099e-03-0.1333image
ENSG00000090565.14,RAB11FIP3BRCABX.795EAG3.4206e-04-0.1584image
ENSG00000090565.14,RAB11FIP3CESCMidostaurinEAG3.6498e-02-0.3498image
chr16:497995-500616:+ESCAA.770041EER4.6631e-04-0.3253image
ENSG00000090565.14,RAB11FIP3ESCAA.770041EAG6.9547e-04-0.3117image
ENSG00000090565.14,RAB11FIP3GBMCGP.082996EAG4.1799e-04-0.3446image
chr16:497995-500616:+GBMCGP.082996EER3.7807e-04-0.3470image
ENSG00000090565.14,RAB11FIP3KIRCCCT007093EAG1.1690e-030.1924image
chr16:492931-494199:+KIRCErlotinibEER8.3743e-03-0.2677image
chr16:495831-496042:+KIRCJW.7.52.1EER1.3322e-03-0.2873image
chr16:497995-500616:+KIRCCCT007093EER4.8943e-040.2067image
chr16:497995-500616:+KIRPGW.441756EER8.1346e-04-0.2645image
ENSG00000090565.14,RAB11FIP3KIRPGW.441756EAG4.8860e-04-0.2751image
chr16:492931-494199:+LAMLLapatinibEER1.7941e-03-0.5229image
chr16:497995-500616:+LAMLBIBW2992EER3.3137e-030.2501image
ENSG00000090565.14,RAB11FIP3LAMLBIBW2992EAG8.6337e-030.2244image
chr16:497995-500616:+LGGBI.D1870EER1.4078e-050.2470image
ENSG00000090565.14,RAB11FIP3LGGBI.D1870EAG1.3383e-050.2468image
ENSG00000090565.14,RAB11FIP3LUADBMS.536924EAG2.9860e-03-0.2409image
chr16:497995-500616:+LUADBMS.536924EER4.4128e-03-0.2312image
ENSG00000090565.14,RAB11FIP3OVMG.132EAG8.7179e-04-0.2494image
chr16:497995-500616:+OVImatinibEER3.0773e-040.2751image
ENSG00000090565.14,RAB11FIP3PCPGA.770041EAG2.6399e-020.4724image
chr16:497995-500616:+PCPGA.770041EER2.5049e-020.4762image
chr16:497995-500616:+PRADGDC0941EER9.6171e-030.3165image
ENSG00000090565.14,RAB11FIP3PRADABT.263EAG3.3275e-04-0.4195image
ENSG00000090565.14,RAB11FIP3SARCAZD6482EAG1.1592e-04-0.5847image
chr16:497995-500616:+SARCAZD6482EER2.8181e-05-0.6456image
ENSG00000090565.14,RAB11FIP3SKCMA.443654EAG1.9211e-020.2699image
chr16:497995-500616:+SKCMA.443654EER1.8767e-020.2708image
chr16:492931-494199:+STADAG.014699EER2.6665e-020.3074image
chr16:497995-500616:+STADBortezomibEER1.5449e-04-0.2632image
ENSG00000090565.14,RAB11FIP3STADMG.132EAG1.0975e-04-0.2631image
ENSG00000090565.14,RAB11FIP3TGCTBryostatin.1EAG9.4858e-030.4004image
chr16:497995-500616:+TGCTBryostatin.1EER1.1643e-020.3903image
chr16:497995-500616:+THCAJNJ.26854165EER3.3546e-030.4638image
ENSG00000090565.14,RAB11FIP3THCAJNJ.26854165EAG3.3299e-030.4642image
chr16:497995-500616:+UCECKIN001.135EER2.1470e-02-0.4327image
ENSG00000090565.14,RAB11FIP3UCECBosutinibEAG3.6291e-030.5145image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType